

Monitoring COVID19 Disease Progression via Cardiac Vibrational Signature Analysis

Company

Name:

Stage:

Device:

Founded:

CardioSounds LLC Ann Arbor, MI 2018 Seed Pre-FDA

Key Words

- Non-invasive sensors
- Signal processing
- Machine learning / Al
- Cardiac monitoring

Unmet Need

CardioSounds addresses an unmet clinical need for advanced, non-invasive, lowcost monitoring of disease progression outside of the **ICU** as manifested in the evolution of cardiovascular system function.

Proposed Solution



- cardiac activity

Preliminary Data



CardioSounds LLC

CardioSensors capture vibrational and electrical signals related to Signal processing and AI algorithms relate signals to indications of physiological state

Methodology has demonstrated potential in prior work

Approach

- Enroll patients admitted to hospital with COVID symptoms
- Collect data (using device); observe outcomes
- Develop AI classification model to predict future outcomes using CardioSounds' algorithms

Outcomes of Interest:

- Ventilator Utilization
- ICU Utilization
- Hemodynamic Instability
- Length-of-Stay / Mortality
- **Study 1**: Tracking systolic arterial line BP in a pharmacological porcine subjects (*N* = 6) exhibiting range of hemodynamic states
- **Study 2**: Classifying human subjects for cuff BP in outpatient setting using rigorous AI model

	Validation Set (2407 cardiac cycles from 9 patient) Target Class		
tion		Normal	High
Prediction	Normal	1110	55
	High	9	1233
		99.2%	95.7%

 Table 2: Classification Matrix

Team

ts)

95.3% 99.3% 97.3%

CardioSounds is supported by an experienced entrepreneurial and clinical team

Kevin Wittrup, MSME, MBA Serial entrepreneur Technology commercialization

Dr. Steven Bolling, MD. University of Michigan Cardiac surgeon

Kayvan Najarian, Ph.D. University of Michigan Machine learning / signal processing

Dr. Rob Sherwin, MD Wayne St. University Emergency medicine / clinical research

Dr. Joe Miller, MD, MS Henry Ford Hospital, Detroit *Emergency medicine / clinical research*

Implementation

- *Technical:* Validate algorithm; evolve design
- *Market/Bus: Establish* strategic partners; secure Series A funding
- **Clinical:** Identify contraindications; establish efficacy & usability
- **Regulatory**: Establish regulatory pathway (510K is presumed)